title: [New approaches for the treatment of dyslipidemia].
abstract: Reduction in the risk of cardiovascular complications through modification of lipids is currently focused on lowering low density lipoproteins-cholesterol, with statins being the preferred drugs. New agents, under research, such as antibodies neutralizing PCSK9, will have a special place for the management of patients with intolerance to statins of severe dyslipemias. Drugs used to modify the concentration of high density lipoproteins-cholesterol and triglycerides have not been accompanied by the expected reductions in the rate of cardiovascular complications.
authors.affiliation: Unidad de Lípidos y Riesgo Cardiovascular, Hospital Carlos III, Madrid, España. Electronic address: jmostaza.hciii@salud.madrid.org.
authors.forename: José María
authors.initials: JM
authors.lastname: Mostaza
authors.affiliation: Unidad de Lípidos y Riesgo Cardiovascular, Hospital Carlos III, Madrid, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Lahoz
mesh_terms: D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
keywords: Cholesterol ester transfer protein inhibitors; Estatinas; Hipercolesterolemia; Hipolipidemiantes; Hypercholesterolemia; Hypolipemiant; Inhibidores de la proteína transportadora de ésteres de colesterol; Proprotein convertase subtilisin/kexin type 9; Proproteína convertasa subtilisina/kexina tipo 9; Statins; Tratamiento de la hipercolesterolemia; Treatment of hypercholesterolemia